Econostrum | Economic News in the Mediterranean

French pharmaceutical company EA Pharma completes acquisition of Italian company Stardea

Written by Frédéric Dubessy on Wednesday, July 13th 2022 à 16:10 | Read 647 times

Stardea is specialized in food supplements (photo: Stardea)
Stardea is specialized in food supplements (photo: Stardea)
FRANCE / ITALY. Côte d'Azur-based EA Pharma is continuing its external growth operations with the acquisition of Italian company Stardea at the beginning of July 2022. This is the fifth acquisition in six years for the French pharmaceutical group based in Sophia-Antipolis, near Nice.

After taking majority stakes in three French companies, Laboratoire Nutrivercell (Duab brand) in 2017, Oligostim in 2019 and Labcatal (Oligosol, Rubozinc and Lithioderm brands) in 2020, Ea Pharma acquired Drasanvi at the end of 2021. The Spanish company specialises in food supplements, natural cosmetics and health nutrition with the brands Super Alimentos, Collmar, Botanical Bio, Immunol and Oseogen, Vital pur.

The arrival of Stardea is part of the French group's new strategy to expand in Europe. Acquired from Cooper Consumer Health, the Italian pharmaceutical group was created in 2005 in Parma. It had been affiliated with Vemedia Pharma (Netherlands) since 2016. It develops a range of dietary supplements, medical devices and dermocosmetics, comprising fifty-six references around nine functional areas: cardiovascular, neurological, respiratory, metabolic, musculoskeletal, gastroentorological, urological, paediatric and dermatological. Its products are distributed in pharmacies through medical recommendations.

Stardea's founder returns to the helm

"This merger will allow the development of innovations and growth for both entities in a very buoyant environment," emphasises Thierry Verne, CEO of EA Pharma. To manage his new Italian subsidiary, he has decided to call on Stardea's founder, Pietro Trascinelli, who will take over his role as CEO.

Italy is the leading European market for food supplements.

Owned by the Paris-based investment fund Motion Equity Partners, EA Pharma (€70m turnover in 2021 and 400 employees) develops a range of oligotherapy drugs, food supplements, cosmetics and sports nutrition products under the Granions, Chondrosteo, Eafit, Foucaud, Punchpower, Conceptio, Duab, Oligostim and Oligosol brands. It has four factories in Europe (Selles-Saint-Denis, Annemasse, Monaco, León in Spain).

In the same section
< >

Tuesday, September 20th 2022 - 15:10 Lebanon will be able to extract its own natural gas


About is an independent media that deals with the daily economic news of the countries bordering the Mediterranean. Economic cooperation, business news by sector (Industry, Services, Transport, Environment, Society/Institutions), thematic files, airport news, airlines and shipping companies (new destinations)... are treated and analysed by a team of journalists present in the Mediterranean basin. Subscribe to To be the first to know, with unlimited access to all articles. To receive the weekly newsletters and special newsletters sent as soon as our files are published. Automatically renewable subscription, but the reader keeps control of it or yearly subscription. For individuals or professionals...